Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors
Sarcomatoid renal cell carcinoma (sRCC) represents a rare form of renal cell carcinoma marked by an aggressive biology, poor prognosis and little benefit from anti-angiogenic targeted therapy. More promising results come from the recent therapeutic strategy based on immune checkpoint inhibitor (ICI) combinations.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Roberto Iacovelli, Chiara Ciccarese, Emilio Bria, Sergio Bracarda, Camillo Porta, Giuseppe Procopio, Giampaolo Tortora Tags: Original Research Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Renal Cell Carcinoma